The The Effect of Mesenchymal Stem Cell Wharton's Jelly on ADAMTS-4 and iNOS Levels in Osteoarthritis Rat Model

Endrinaldi Endrinaldi; Eryati Darwin; Nasrul Zubir; Gusti Revilla

doi:10.3889/oamjms.2019.155

Authors

Endrinaldi Endrinaldi Doctoral Student of Postgraduate Biomedical Science, Faculty of Medicine, Andalas University, Padang, Indonesia; Department of Chemistry, Faculty of Medicine, Andalas University, Padang, Indonesia
Eryati Darwin Department of Histology, Faculty of Medicine, Andalas University, Padang, Indonesia
Nasrul Zubir Department of Internal Medicine, Faculty of Medicine, Andalas University, Padang, Indonesia
Gusti Revilla Department of Anatomy, Faculty of Medicine, Andalas University, Padang, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2019.155

Keywords:

ADAMTS-4, iNOS, Mesenchymal Stem Cell Wharton Jelly, Osteoarthritis

Abstract

BACKGROUND: Osteoarthritis (OA) is one of the most common diseases among the elderly. OA occurs due to an imbalance between degradation and synthesis in articular joint tissue, causing changes in joint components such as cells, matrices and molecular production. Therefore, knowledge of cartilage-degrading enzymes such as ADAMTS-4 and iNOS is needed.

AIM: This study aims to prove the effect of Mesenchymal Stem Cell Wharton Jelly on decreasing ADAMTS-4 levels as cartilage-degrading enzymes and increasing levels of iNOS which showed the immunosuppressive potential of MSC-WJ in cases of osteoarthritis in vivo.

MATERIAL AND METHODS: This research is an experimental study with the design of Post-test-Only Control Group Design. The sample consisted of 16 OA rats as a control group and 16 OA rats treated with MSC-WJ as a treatment group. OA induction is done by injection of monosodium iodoacetate (MIA) into the intra-articular right knee. Giving MSC-WJ is done in the third week after MIA induction. The serum ADAMTS-4 and iNOS levels were measured after 3 weeks treated with MSC-WJ using the ELISA method. The statistical test used is an independent t-test. The value of p < 0.05 was said to be statistically significant.

RESULT: The result showed that serum ADAMTS-4 levels were lower in the group treated with MSC-WJ than in the control group, but not statistically significant (p > 0.05). Serum iNOS levels were higher in the group treated with MSC-WJ than in the control group (p < 0.05).

CONCLUSION: This study concluded that MSC-WJ significantly reduced ADAMTS-4 levels and increased the serum iNOS levels of OA rats.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Kraus VB, Blanco FJ, Englund M, Karsdal MA, Lohmander LS. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage. 2015; 23(8):1233-41. https://doi.org/10.1016/j.joca.2015.03.036 PMid:25865392 PMCid:PMC4516635

Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkBa into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kB-dependent. J Rheumatol. 2007; 34:523-33.

Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease : Potential Implication for the Selection of New Therapeutic Targets. Arthritis Rheum. 2001; 44:1237-47. https://doi.org/10.1002/1529-0131(200106)44:6<1237::AID-ART214>3.0.CO;2-F

Benito MJ, Veale DJ, Fitzgerald O, Van Den Berg WB, Bresnihan B. Synovial tissue infl ammation in early and late osteoarthritis. Ann Rheum Dis. 2005; 64:1263-7. https://doi.org/10.1136/ard.2004.025270 PMid:15731292 PMCid:PMC1755629

Fan Z, Bau B, Yang H, Soeder S, Aigner T. Freshly isolated osteoarthritic chondrocytes are catabolically more active than normal chondrocytes, but less responsive to catabolic stimulation with interleukin-1ÃŸ. Arthritis Rheum. 2005; 52:136-43. https://doi.org/10.1002/art.20725 PMid:15641077

Bondeson J, Lauder S, Wainwright S, et al. Adenoviral gene transfer of the endogenous inhibitor IkBa into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kB-dependent. J Rheumatol. 2007; 34:523-33.

Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007; 213:341-34. https://doi.org/10.1002/jcp.21200 PMid:17620285

Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363:1439-1441. https://doi.org/10.1016/S0140-6736(04)16104-7

Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide. Cell Stem Cell. 2008; 2:141-150. https://doi.org/10.1016/j.stem.2007.11.014 PMid:18371435

Shi Y, Hu G, Su J, Li W, Chen Q, Shou P, Xu C, Chen X, Huang Y, Zhu Z, Huang X, Han X, Xie N, Ren G. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res. 2010; 20:510-518. https://doi.org/10.1038/cr.2010.44 PMid:20368733

van Buul GM, Siebelt M, Leijs MJC, Bos PK, Waarsing JH, Kops N, et al. Mesenchymal Stem Cells Reduce Pain But Not Degenerative Changes in a Mono-Iodoacetate Rat Model of Osteoarthritis. J Orthop Res. 2014; 32:1167-1174. https://doi.org/10.1002/jor.22650 PMid:24839120

Javanmard MZ, Asgari D, Karimipour M, Atabaki F, Farjah G, Niakani A. Mesenchymal Stem Cells Inhibit Proteoglycan Degeneration in a Rat Model of Osteoarthritis. Gene Cell Tisue. 2015; 2(4):e31011:1-5. https://doi.org/10.17795/gct-31011

Naito S, Shiomi T, Okada A, Kimura T, Chijiiwa M, Fujita Y, Yatabe T, Komiya K, Enomoto H, Fujikawa K, Okada Y. Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathology International. 2007; 57:703-711. https://doi.org/10.1111/j.1440-1827.2007.02167.x PMid:17922681

Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013; 141:1-10. https://doi.org/10.1038/nrrheum.2013.141

Shu C C, Ravi V, Zaki S, Smith S M, Schiavinato A, Smith MM, Little CB. The Effects Of Intra-Articular Injection Of Mesenchymal Stem Cells Versus Hyaluronan Hexadecylamide- Derivative on Post-Traumatic OA: The Relationship Between Synovial Inflammation, Structural Pathology and Pain Sensitisation. Osteoarthritis and Cartilage. 2016; 24:S63-S534. https://doi.org/10.1016/j.joca.2016.01.580

van Buul GM, Villafuertes E, Bos PK, Waarsing JH, Kops N, Narcisi R, et al. Mesenchymal stem cells secrete factors that inhibit inflammatory processes in short-term osteoarthritic synovium and cartilage explant culture. Osteoarthritis Cartilage. 2012; 20:1186-1196. https://doi.org/10.1016/j.joca.2012.06.003 PMid:22771777

Yun S, Ku SK, Kwon YS. Adipose-derived mesenchymal stem cells and platelet-rich plasma synergistically ameliorate the surgical-induced osteoarthritis in Beagle dogs. Journal of Orthopaedic Surgery and Research. 2016; 11(9):1-12. https://doi.org/10.1186/s13018-016-0342-9

Leonidou A, Lepetsos P, Mintzas M, Kenanidis E, Macheras G, Tzetis M, Potoupnis M, Tsiridis E. Inducible nitric oxide synthase as a target for osteoarthritis treatment. Expert Opinion on Therapeutic Targets. 2018:1-20. https://doi.org/10.1080/14728222.2018.1448062

Xu C, Ren G, Cao G, Chen Q, Shou P, Zheng C, Du L, Han X, Jiang M, Yang Q, Lin L. miR-155 regulates immune modulatory properties of mesenchymal stem cells by targeting TAK1-binding protein 2. Journal of Biological Chemistry. 2013; 288(16):11074-9. https://doi.org/10.1074/jbc.M112.414862 PMid:23449975 PMCid:PMC3630877

Bouffi C, Djouad F, Mathieu M, Noel D, Jorgensen C. Multipotent mesenchymal stromal cells and rheumatoid arthritis: risk or benefit? Rheumatology. 2009; 48(10):1185-9. https://doi.org/10.1093/rheumatology/kep162 PMid:19561159

Gieseke F, BÃ¶hringer J, Bussolari R, Dominici M, Handgretinger R, MÃ¼ller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood. 2010; 116:3770-3779. https://doi.org/10.1182/blood-2010-02-270777 PMid:20644118

Li F, Xiong F, Zhang Y, Li Y, Zhao H, Cho SC, Ichim TE, Yang X, Hu X. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells against acute tubular necrosis quantified through measures of iNOS, BMP-7 and Bcl-2. Open Journal of Regenerative Medicine. 2013; 2(02):31-38. https://doi.org/10.4236/ojrm.2013.22006

Cosenza S, Ruiz M, Toupet K, Jorgensen C, NoÃ«l D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Scientific Reports. 2017; 7(1):16214. https://doi.org/10.1038/s41598-017-15376-8 PMid:29176667 PMCid:PMC5701135

Xu Y, Luo H, Chen F, Shi Y, Sun M. Human umbilical cord mesenchymal stem cells polarize RAW264.7 macrophages to an anti-inflammatory subpopulation. Int J Clin Exp Pathol. 2018; 11(3):1446-1452.

Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, Muroi K, Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood. 2007; 109:228-234. https://doi.org/10.1182/blood-2006-02-002246 PMid:16985180

Carrade Holt DD, Wood JA, Granick JL, Walker NJ, Clark KC, Borjesson DL. Equine mesenchymal stem cells inhibit T cell proliferation through different mechanisms depending on tissue source. Stem Cells Dev. 2014; 23:1258-1265. https://doi.org/10.1089/scd.2013.0537 PMid:24438346

Wang M, Yuan Q, Xie L. Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. Stem Cells International. 2018. https://doi.org/10.1155/2018/3057624